GlassScriptPhysician profile
Brian W Heiniger
NPI 1528452463
$4,312.15
in general payments reported to CMS, 2019-2025
21 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $180 · 2021: $432 · 2022: $525 · 2023: $657 · 2024: $548 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.88 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,290.25 | 2019-2025 | Idosetr, Kxl System (Not Refurbished), Istent Infinite |
| Biotissue Holdings INC. | $908.71 | 2022-2025 | |
| Alcon Vision LLC | $677.89 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $240.44 | 2019-2025 | |
| Sight Sciences, INC. | $190.08 | 2022-2023 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $156.78 | 2019 | |
| Ocular Therapeutix, INC. | $139.15 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $125.38 | 2023-2025 | Acthar |
| Oyster Point Pharma, INC. | $89.54 | 2022-2025 | Tyrvaya |
| Rxsight INC | $83.57 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $65.49 | 2024-2025 | Xiidra, Miebo |
| Carl Zeiss Meditec, INC. | $60.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $48.42 | 2025 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $48.23 | 2023-2024 | Iheezo |
| Abbvie INC. | $47.26 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $41.56 | 2023-2025 | Oxervate |
| New World Medical,INC. | $29.32 | 2023 | |
| Travere Therapeutics, INC. | $24.19 | 2021 | |
| Lensar, INC. | $17.42 | 2025 | Lensar Laser System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Heiniger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.